急性ST段抬高型心肌梗死溶栓治疗后经皮冠状动脉介入治疗118例分析

Analysis of 118 Cases of Percutaneous Coronary Intervention after Thrombolytic Therapy for Acute ST-segment Elevation Myocardial Infarction

目的分析急性ST段抬高型心肌梗死患者经溶栓治疗后再行经皮冠状动脉介入(PCI)治疗的临床疗效。方法选该院2017年12月-2018年12月收治的118例急性ST段抬高型心肌梗死患者分组研究,依据是否有PCI治疗进行分组(每组59例),其中PCI组由PCI介入治疗,而药物组仅由药物进行治疗,比较其临床疗效。结果PCI组对于抗血小板制剂、血管紧张素转换酶抑制剂、β受体阻滞剂以及他汀类药物服药率分别为77.97%、32.20%、45.76%、55.93%;另外,患者住院期间,PCI组患者的左心室射血分数、死亡率、再发心绞痛、心肌梗死以及心力衰竭发生率分别为(60.9±7.9)分、5.08%、3.39%、6.78%,药物组患者的死亡率、再发心绞痛、心肌梗死以及心力衰竭发生率分别为(56.1±6.8)分、16.95%、15.25%、22.03%,两组相比,差异有统计学意义(t=14.009,P=0.027;χ^2=4.929、4.929、6.011,P<0.05)。结论急性ST段抬高型心肌梗死患者经溶栓治疗后再行经皮冠状动脉介入(PCI)治疗的措施疗效卓越,显著优于药物治疗。

Objective To analyze the clinical efficacy of percutaneous coronary intervention(PCI)after thrombolytic therapy in patients with acute ST-segment elevation myocardial infarction.Methods A total of 118 patients with acute ST-segment elevation myocardial infarction admitted to our hospital from December 2017 to December 2018 were enrolled in this study.The patients were divided into two groups according to whether there were PCI treatment(59 cases in each group).PCI group was treated with PCI.The drug group was treated only with drugs,and its clinical efficacy was compared.Results In the PCI group,the rates of antiplatelet agents,angiotensin-converting enzyme inhibitors,beta blockers,and statins were 77.97%,32.20%,45.76%,and 55.93%,respectively.In addition,patients were hospitalized during the PCI group.The patients’ left ventricular ejection fraction,mortality,recurrent angina pectoris,myocardial infarction,and heart failure were(60.9±7.9)points,5.08%,3.39%,and 6.78%,respectively,mortality in the drug group,recurrent angina,the incidence of myocardial infarction and heart failure were(56.1±6.8)points,16.95%,15.25%,and22.03%,respectively,and the difference was significant in the two groups(t=14.009,P=0.027;χ^2=4.929,4.929,6.011,P<0.05).Conclusion Patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention(PCI)after thrombolytictherapy are superior in efficacy and significantly superior to drug therapy.